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Summary: A sensitive HPLC method is reported for the Simultaneous determination of theophylline, caffeine,
and phenobarbital in 100 of plasma.
After a single extraction of the drugs with chloroform/isopropanol (90 4-10 by volume) at low pH in the
presence of an excess of ammonium sulphate they are resolved and quantified using a reversed-phase column
(Spherisorb 5 ODS). The drugs are eluted with a binary-solvent gradient System (acetonitrile/phosphate
buffer pH 4.6) at room temperature and monitored at 204 nm. Quantitation is based on peak-height ratio
of analyte tp interval Standard (8-chlorotheophylline).
Complete Chromatographie resolution of all drugs is achieved within 15 min. The method is linear to 40 mg/1
\ of theophylline and caffeine, and to 80 mg/1 of phenobarbital. Numerous drugs and xanthine metabolites
P tested do not interfere.
o
Hochleistungsflüssigkeitschromatographisches Verfahren für die gleichzeitige Bestimmung von Theophyllin,
j Coffein und Phenobarbital bei Neugeborenen
: Zusammenfassung: Eine empfindliche hochleistungsflüssigkeitschromatographische Methode für die gleich-
I zeitige Bestimmung von Theophyllin, Coffein und Phenobarbital in Plasma wird beschrieben.
Nach Extraktion der Arzneimittel mit Chloroform/isopropanol (90-1-10, Volumina) bei niedrigem pH in
Gegenwart eines Überschusses von Ammoniumsulfat erfolgen Trennung und Quantifizierung mit einer
„reversed-phase"-Säule an Spherisorb 5 ODS. Die Arzneimittel werden bei Raumtemperatur mit einem
binären Lösungsmittelgradienten (Acetonitril/Phosphatpüffer pH 4,6) eluiert und bei 204 nm gemessen. Die
Auswertung erfolgt aufgrund des Peajkhöhen-Verhältnisses von Analyt und 8-Chlortheophyllin als internem
l Standard.
Die vollständige chromatographische Trennung der drei Arzneimittel wird innerhalb 15 Minuten erreicht.
j Die Methode ist linear bis 40 mg/1 Theophyllin und Coffein und bis 80 mg/1 Phenobarbital. Zahlreiche
! Arzneimittel und Xanthinmetabolite wurden geprüft und stören das Verfahren nicht.
n ro ucnon caffeine, reaching medically significant levels in
Theophylline (1,,3-dimethylxanthine) and caffeine plasma (2, 3). For this reason, it is important to
(1,3,7-triinethylxanthine) are two drugs widely used determine both drugs simultaneously in order to es-
in the prevention and treatment of neonatal apnoea tablish an optimal individual dose and to prevent
(1). In neonates, theophylline is metabolized to toxicity.
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Recently, several HPLC methods have been de-
veloped for the analysis of theophylline, caffeine,
and other methylated xanthines (4 — 6). However, no
method has s yet been reported which permits the
simultaneous determination of phenobarbital to-
gether with these drugs in a reasonable time period.
Phenobarbital is, however, widely used s an enzyme
inducer to prevent hyperbilirubinaemia in preterm
neonates (7, 8). In addition, it is used in the treatment
of convulsions, and it is sometimes used in combin-
ation with theophylline in the treatment of apnoea.
The half-life of this drug in neonates is relatively long
with a wide interindividual variability (9 — 11). Thus,
the simultaneous determination of phenobarbital
would be very useful in order to avoid toxicity
Symptoms of this drug in neonates.
We report here a gradient reversed-phase liquid
Chromatographie method for a rapid, simultanqous
determination of theophylline, caffeine, and phe-
nobarbital in plasma. Plasma (100 μΐ) was extracted,
using an efficient single-step method, which can also
be adapted to 50 μΐ if necessary.
Materials and Methods
We used a Kontron HPLC System Model 620 (Z rich, Switzer-
land) coupled to a Uvikon variable wavelength ultraviolet spec-
trophotometer Model 720LC (Kontron AG), a Kontron pro-
grammer Model 200, and a Hewlett-Packard integratpr Model
3390A (Avondale, PA 19311, U.S.A.). The column used was a
Spherisorb ODS column, 5 micron particle size, 250 mm χ 4.6
mm i.d. (Kontron AG). Samples were injected using a
Rheodyne injector Model 7125 with a 20 μΐ loop.
Reagents and Standards
Acetonitrile was of HPLC grade (Fisher Scientific Co., Fair
Lawn, NJ 07410, U.S.A.). Methanol, Chloroform, and
isopropanol were LiChrosolv® (Merck, Darmstadt, F.R.G.).
All the inorganic chemicals were of A. R. grade (Merck). HPLC
grade water was prepared with the Norganic water purification
System (Millipore Corp., Bedford, M A 01730, U.S. A.).
Theophylline, caffeine, and 8-chlorotheophylline were
purchased from Sigma Chemical Corp..(St. Louis, MO 63178,
U.S.A.). Phenobarbital was a gift from Bayer Laboratories
(Barcelona, Spain).
Stock Standards: these were prepared in methanol to give a
concentration of 500 mg/1 for theophyiline, caffeine and 8-
chlorotheophylline, and l g/l for phenobarbital.
Plasma Standards: these were prepared in df ug^free plasma in
the r nge 0.5-40 mg/1 (theophylline, caffeine) and 5-80 mg/1
-(phenobarbital).
Internal Standard solution: this was prepared daily in water to
give a concentration of 10 mg/1.
Phosphate buffer: add 150 μΐ of l mol/1 KH2PO4 to 1000 ml of
water and adjust to pH 4.6 with 0.9 mol/1 H3PO4.
Mobile phase: solvent A — phosphate buffer; solvent B —
acetonitrile. Before use, the organic solvent was filtered and
degassed by passing i t through a 0.5 μπι Millipore filter type
FHUPO4700 (Millipore Corp.) under reduced pressure. The
buffer was passed under reduced pressure through a 0.45 μιη
Millipore filter type HATF047EP.
Extraction solvent: chloroform/isopropanol (90-h 10 by
volume). ·'r
Procedure
Plasma (100 μΐ), internal Standard (100 μΐ) and one drop of 3
mol/1 HC1 are added to a glass stoppered centrifuge tube, then
mixed by vortexing for 5 s. Extraetion solvent (2.5 ml) is then
added. After mixing (voftex) for 30 s, about 200 mg of crystal·
line ammonium sulphate re added with the aid of a calibfated
spatula, and the tube contents are again mixed vigorously
(vortex) for 30 s. After centrifugation at 5000 min"1 for about
3 min, the upper aqueous layer is aspirated and discarded, and
the organic phase is decanted into a conical glass tube. Two
millilitres of this organic phase are transferred by pipette to a
second conical glass tube then evaporated to dryness at 60 °C
in a water bath under a gentle stream of air.
The dry residue is dissolved in methanol (50 μΐ) and 20 μΐ of
this solution are injected into the Chromatograph, maintaining
a flow rate of 3 ml/min. The effluent is monitored at 204 nm.
The mobile phase comppsition is programmed s follows: The
initial composition of solvents A/B is 97 + 3 by volume. From
time 0 to 15 min, a linear gradient proceeds to a composition
of solvents A/B, 67-1-33 by volume. Frpm 15 to 15.5 min,
linear gradient returns to the initial composition, llowing
immediate injection of another sample. Chromatogr phy is
performed at room temperature.
Quantification is based on the peak-height ratio of the analyte
to the internal Standard.
Results
Chromatograms
Figure l shows typical chromatpgrams obtained with
the reported procedure from extracts of a plasma
blank and a plasma spiked with therape tic levels of
the assayed drugs.
Linearity
We have investigated the linearity of the peak-height
ratios versus plasma drug concentrations in the
following ranges: 0.5-40 mg/1 for theophylline and
caffeine, and 5-80 mg/1 for phenobarbital. Results
obtained using a linear regression analysis were:
theophylline:
slope = 0.131 y-intercept = 0.022 r = 0.999
caffeine:
slope = 0.126 y-intercept = 0.010 r = 0.999
„phenobarbital:
slope = 0.400 y-intercept = Q.OOO r = 0.999
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Fig. 1. Chromatogram of (left) a blank plasma and (right) a u u· t
spiked plasma containing per litre: 10 mg of theophyl- ™enobarbital
line (1), 10mg of caffeine (3), and 20mg of phe-
nobarbital (4). Peak (2) is the internal Standard and





shown in table 2, re-























































The precision of the method was determined by assay-
ing plasma samples containing known quantities of
the drugs. As shown in table l, within-day precision
ranged from 1.2 to 6.2, and between-day precision
ranged from 1.6 to 6.7%.





























































































We determined the analytical recovery of the assayed
drugs from plasma by cpmparing the peak-height
Interferences
Table 3 shows the retention time of the drugs tested
for potential interference relative to the internal Stan-
dard. Of these drugs, only paraxanthine (1,7-
dimethylxanthine), a metabolite of caffeine, co-elutes
with theophylline. However, paraxanthine, which
may exist in patients consuming coffee, is not present
in the plasma of neonates (2,12). Drugs tested but not
eluted within 15 min were: phenytoin, clonazepam,
carbamazepine, diazepam, and methaqualone.













































J. Clin. Chem. Clin. Biochem. / Vol. 23,1985 / No. 5
306 Soto-Olero, Mendez-Alvarcz and Sierra-Marcuno: Simultaneous determinalion of theophylline, caffeine and phenobarbital
Discussion
We performed the extraction with a mixture of
organic solvents in the presence of excess of am-
monium sulphate. This procedure causes virtually
complete precipitation of plasma proteins (13), which
otherwise would contaminate the column and the
injection System (14). The use of a low pH improves
the analytical recovery of some drugs and allows the
precipitation of some plasma lipid components. In
the extraction we recommend vigorous vortex-mixing
for a few seconds rather than continous vortexing, in
order to avoid the formation of an emulsion. We used
methanol to redissolve the dried extract because it
does not affect the shape of peaks and, furthermore,
increases the analytical recovery of theophylline.
We found it necessary to use a mobile-phase gradient
because low concentrations of acetonitrile are essen-
tial for a good resolution of theophylline, caffeine,
and some of their metabolites, while high con-
centrations of acetonitrile are necessary for a rapid
elution of phenobarbital. 8-Chlorotheophylline was
chosen äs internal Standard for its position in the
chromatogram and for its good analytical recovery.
Phosphate buffer pH 4.6 was föürid to play an
important role in obtaining a good resolution be-
tween caffeine and the internal Standard. The column
efflüent was monitored at 204 nm because this wäve-
length provides adequate sensivity for all the assayed
drugs.
To prevent büild-üp of any strongly retained mat·^
erials on the HPLC column, the Chromatographie
System was purged at the end of each workday with
water for 15 min followed by acetonitrile for othef
15 min, at a flow rate of 3 ml/min.
The method äs repörted here uses 100 of plasma,
but its high sensitivity permits adaptatiori to 50 if
desirable.
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